Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2021
Myovant Sciences Ltd.
(Exact name of registrant as specified in its charter)

(Commission File No.)

(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)

Suite 1, 3rd Floor
Not Applicable
11-12 St. James’s Square
(Zip Code)
United Kingdom
(Address of principal executive offices)
Registrant’s telephone number, including area code: +44 207 400 3351
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Shares, par value $0.000017727 per share
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 1, 2021, Ms. Kathleen Sebelius notified the board of directors (the “Board”) of Myovant Sciences Ltd. of her intention to retire from service on the Board upon expiration of her current term, and therefore, that she will not stand for re-election to the Board at Myovant’s annual general meeting of shareholders to be held in 2021. Ms. Sebelius’ decision not to stand for re-election to the Board is not the result of any disagreement with Myovant. Myovant extends its deepest gratitude to Ms. Sebelius for her distinguished service to the Board and lasting contributions to Myovant.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Myovant Sciences Ltd.
June 4, 2021
/s/ Matthew Lang
Matthew Lang
General Counsel and Corporate Secretary